Fresenius Kabi has marked the start of US biosimilar competition to Actemra (tocilizumab), launching its Tyenne (tocilizumab-aazg) version in an intravenous formulation, which it said would provide “increased access and an affordable, high-quality, and safe treatment option for US patients.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?